New research identifies a key microglial subpopulation regulated by anti-TREM2 antibody therapy in Alzheimer's disease, revealing how the treatment guides microglia toward protective differentiation pathways.
Ultragenyx will lay off 130 employees as part of restructuring aimed at profitability by 2027. The FDA rejected the company's gene therapy application for Sanfilippo syndrome due to manufacturing concerns.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05524922 |
A Registered Cohort Study on Neurodegenerative Associated With Sleep Disorder. |
RECRUITING |
